Facioscapulohumeral muscular dystrophy has a characteristic descending pattern of weakness, first affecting the face and shoulder followed by the distal lower extremity and the proximal hip girdle muscles, but many variations in the presentation can occur.
There are no registered therapies approved for FSHD. Although many drugs have been tested in clinical trials (prednisone diltiazem, albuterol, and a myostatin inhibitor), none showed a clear benefit. Stretching and range of motion exercises are also recommended (43, 44, 47) anormally silenced gene DUX4 (double homeobox 4).
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD)
X-linked recessive allelic disorders caused by mutations in the dystrophin gene
Dystrophin
The absence of dystrophin leads to progressive muscle necrosis, loss of independent ambulation by early adolescence, cardiomyopathy, respiratory insufficiency, and premature death in DMD individuals. BMD is caused by mutations in the same gene, leading to the production of an altered protein and the late onset of symptoms. BMD patients also have skeletal muscle weakness, but cardiac dysfunction in more pronounced So far, therapy aimed at a complete recovery has not been developed for these diseases. The most appropriate therapy would be complementation or restoration of dystrophin expression, such as gene therapy using viral vectors, read through therapy, or exon skipping therapy.
(56, 59, 60)
Emery-Dreifuss Muscular Dystrophy (EDMD)
Associated with mutations in the emerin gene (EMD) located in the X chromosome and other genes, such as FHL1, LMNA, SYNE1, SYNE2 
Oculopharyngeal muscular dystrophy (OPMD)
Repeat expansion in the PABPN1 gene that results in an N-terminal expanded polyalanine tract in polyA-binding protein nuclear 1 (PABPN1) polyadenylate binding protein (PABPN1) OPMD is mainly characterized by progressive eyelid drooping, swallowing difficulties (as the pharyngeal muscles are mostly affected) and proximal limb weakness.
No cure is currently available to arrest the disease. Surgical pharyngeal myotomy is the only treatment available to improve swallowing in these patients. Pharmacological therapies, currently under pre-clinical investigation, include antiprion drugs like 6-aminophenanthridine and guanabenz, and targeting the expPABPN1 using intracellular antibodies. However, none of these strategies directly correct the genetic defect of OPMD patients.
(21-23)
Congenital muscular dystrophy (CMD)
There are more than 13 genes associated with CMD. Among them are: 
